Differences in gene expression in CRPC cell line C4-2 before and after Cyclin-Dependent Kinase 12 (CDK12) knockdown using CRISPR-Cas9

CDK12 is a transcription-related CDK that is commonly mutated in different types of cancers. In prostate cancer, defective CDK12 has been identified as a new subtype with a worse prognosis and widespread drug resistance. CRPC is a malignant stage of recurrent prostate cancer following treatment, with a higher frequency of CDK12 mutations compared to early-stage prostate cancer. To investigate the impact of CDK12 defects on the overall gene expression in CRPC cells, we used CRISPR-Cas9 technology to generate CDK12 knockout and control C4-2 cell lines, followed by high-throughput transcriptome sequencing (RNA-seq). Our results demonstrate that CDK12 defects affect the expression of numerous genes in CRPC cells, providing insights into the regulatory role of CDK12 in prostate cancer development. To investigate the effects of CDK12 deficiency on CRPC cells. We constructed CDK12 knockout and control cell lines using CRISPR-Cas9 technology. Next, we extracted total RNA from the cells and performed high-throughput transcriptome sequencing. We then performed gene expression profiling analysis using data obtained from RNA-seq and comparative gene expression profiling analysis of RNA-seg data for C4-2 VEC cell and its KO derivatives (VEC, CDK12KO)—three replicates per sample.